1. Scrip
  2. >>Business
  3. >>Strategy

Best Practices For Offering Value To Potential Partners – Highlights From LSX

 
• By Joseph Haas

At the 2024 LSX USA conference, panelists provided advice on how to approach companies in dealmaking and to make their value proposition fit with what the company is looking for.

Biz advice
Speakers at LSX USA 2024 offered best practices for dealmaking • Source: Shutterstock

With the flow of initial public offerings frustratingly sluggish and a tight financing environment, biopharma companies are looking for advice on other ways to bring in funding capital or explore business development options. In challenging times, experts agree it can be good to fall back on best practices.

Key Takeaways

  • Panelists at the recent LSX USA meeting offered advice to biotechs on how to approach partnering with deep-pocketed firms.

At the LSX World Congress USA, held 11-12 September in Boston, speakers from biopharma and other life sciences firms were...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Biopharma Financing Veers Toward Optimism, But Cell And Gene Therapies Left Behind

 
• By Mandy Jackson

While there may be the beginnings of a turnaround in biopharma capital markets, gains in the cell and gene therapy space may lag the broader sector recovery, noted speakers at ARM’s Cell and Gene Meeting on the Mesa.

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By Kevin Grogan

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Ribomic Positions Itself As Latest Potential Achondroplasia Competitor

 
• By Alaric DeArment

The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.

More from Business

Ribomic Positions Itself As Latest Potential Achondroplasia Competitor

 
• By Alaric DeArment

The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Stock Watch: Baby Steps In Most Favored Nation Drug Pricing

 
• By Andy Smith

Raising UK drug prices and offering lower list prices only to those US patients who are under- or uninsured were the industry’s initially cosmetic answers to the administration’s most favored nation drug pricing challenge. Then Pfizer stepped in.